Want to see TSE:AVCN full AI Analyst Report?
Avicanna (AVCN) AI Stock Analysis
Avicanna
(TSX:AVCN)
Financial performance drives the score with revenue growth and balance sheet strength, tempered by weak technical indicators and negative valuation metrics due to ongoing losses.
Avicanna (AVCN) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 10.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 98.20K
- Price to Earnings (P/E)
- -3.2
- Beta (1Y)
- 1.43
- Revenue Growth
- -0.23%
- EPS Growth
- -142.54%
- Country
- Canada
- Employees
- 112
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Avicanna Business Overview & Revenue Model
Company Description
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health ma...
How the Company Makes Money
Avicanna makes money primarily by selling cannabinoid-based products and related services through regulated medical and pharmaceutical channels. Key revenue streams include: (1) Product sales: revenue from finished, formulated cannabis/cannabinoid pr...
Avicanna Earnings Call Summary
The call emphasized material operational and scientific progress—improved gross margins (53%, +10 pts), reduced operating expenses (–9%), stronger liquidity (working capital +23%), R&D/IP milestones (PwdRX/data and new USPTO patent), and clinical advancements (450 patient RWE study published; Phase II underway). These positives were tempered by flat top-line revenue at $25.5M, a still-negative full-year adjusted EBITDA (–$300k) and net loss ($2.7M), early-stage commercial launches (soft launch of Trunerox) and ongoing regulatory and market uncertainties (U.S. rescheduling dependency and stock overhang). On balance, the company presented clear momentum on margins, efficiency, IP and clinical programs while acknowledging remaining commercialization and market-risk headwinds.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance for 2026 targets continued profitable, capital-light scaling: management plans to internationalize RHO Phyto and roll out 3.0 fast-acting products while leveraging two new delivery platforms finalized in 2025 (in fluid and PwdRX — PwdRX showed a 74% increase in bioavailability, 63% higher peak plasma concentration and 134% higher peak concentration versus MCT oil in vitro). Key numeric goals and context: 2025 revenue was $25.5M (MyMedi $20.4M), gross profit $13.5M (53% margin, +10% vs 2024), adjusted EBITDA loss improved to $300k (71% improvement vs a $1.0M loss in 2024) with Q4 adjusted EBITDA positive $310k, net loss down 41% to $2.7M, working capital +23%, only $1.0M raised in 2025 (vs $4.8M in 2024), no debt, 50 Canadian SKUs with 170 listings ( listings +26% YoY), presence in 24 markets and a planned Australia launch (6th continent), continued RWE (≈450 patients) and active Phase I/II trials, plus scaling exports from Aureus (international revenue ~$1.9M) and pursuit of a U.S. senior-exchange listing.
Avicanna Financial Statement Overview
Summary
Revenue scaled to $25.3M with 52% gross margins and narrowed losses; strong balance sheet with positive equity and low debt, though negative cash flows persist.
Income Statement
62PositiveBalance Sheet
82Very PositiveCash Flow
48Neutral| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.31M | 25.48M | 25.46M | 16.79M | 4.05M | 3.27M |
| Gross Profit | 13.13M | 12.84M | 12.90M | 6.66M | 1.11M | 2.83M |
| EBITDA | -3.04M | -1.97M | -2.43M | -7.36M | -12.18M | -15.13M |
| Net Income | -3.91M | -2.84M | -3.62M | -8.74M | -14.73M | -16.77M |
Balance Sheet | ||||||
| Total Assets | 24.13M | 21.24M | 20.12M | 21.97M | 17.62M | 22.30M |
| Cash, Cash Equivalents and Short-Term Investments | 200.42K | 280.63K | 448.03K | 477.20K | 1.19M | 31.00K |
| Total Debt | 169.56K | 0 | 109.23K | 1.80M | 3.21M | 1.66M |
| Total Liabilities | 10.12M | 9.86M | 10.38M | 14.00M | 14.16M | 15.39M |
| Stockholders Equity | 4.60M | 2.84M | 2.31M | -112.50K | -383.56K | 1.15M |
Cash Flow | ||||||
| Free Cash Flow | -3.36M | -1.44M | -2.95M | -1.96M | -7.50M | -12.45M |
| Operating Cash Flow | -3.15M | -1.18M | -2.55M | -1.40M | -7.44M | -11.66M |
| Investing Cash Flow | -207.88K | -255.84K | -402.57K | -3.05M | 810.24K | 760.83K |
| Financing Cash Flow | 3.20M | 963.17K | 3.41M | 3.55M | 9.90M | 10.06M |
Avicanna Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCN, the sentiment is Neutral. The current price of 0.10 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 49.56 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:AVCN.
Avicanna Peers Comparison
Overall Rating
- TSE:AVCN54Neutral
TSE:CWEB53Neutral
TSE:LABS49Neutral
TSE:CRDL42Neutral
TSE:INNO41Neutral
TSE:PCLO24Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:AVCN | 54Neutral | CAD 14.11M | -3.24 | -108.44% | ― | -0.23% | -142.54% |
| TSE:CWEB | 53Neutral | CAD 84.10M | -1.06 | -285.96% | ― | -7.77% | -52.56% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:LABS | 49Neutral | CAD 27.77M | -5.60 | -13.79% | ― | -6.74% | 43.54% |
| TSE:CRDL | 42Neutral | CAD 195.47M | -4.71 | -180.13% | ― | ― | 29.34% |
| TSE:INNO | 41Neutral | CAD 8.55M | -6.57 | -19.37% | ― | -19.20% | 42.54% |
| TSE:PCLO | 24Underperform | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:AVCN | Avicanna Inc | 0.10 | -0.16 | -60.38% | |
| TSE:CWEB | Charlotte's Web Holdings (OTC) | 0.31 | 0.11 | 55.00% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -13.33% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:CRDL | Cardiol Therapeutics Inc. | 1.62 | 0.08 | 5.19% | |
| TSE:INNO | Innocan Pharma Corporation | 1.90 | -16.10 | -89.44% |
Avicanna Corporate Events
Avicanna Secures Strategic Private Placement Led by Pharma Investor Michael Porter
PositiveAvicanna Inc., a biopharmaceutical company focused on plant-derived cannabinoid-based products for global medical and pharmaceutical markets, has built a diversified platform spanning branded medical cannabis, a patient-centric care portal, clinical-...
Avicanna Lifts Margins and Expands Portfolio Ahead of QUIX Launch Despite VAC Headwinds
PositiveAvicanna reported Q2 2026 revenue of $5.64 million, down 8% year over year, as reduced Veterans Affairs Canada reimbursement rates and timing of certain business unit revenues weighed on sales. Despite this, proprietary product volumes rose 33% year...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 09, 2026